New Medicine Service (NMS)
New Medicine Service (NMS)
The New Medicine Service (NMS) was the fourth Advanced Service to be added to the Community Pharmacy Contractual Framework; it commenced on 1st October 2011.
The service provides support for people with long-term conditions newly prescribed a medicine to help improve medicines adherence; it is initially focused on particular patient groups and conditions.
Since the introduction of the NMS in October 2011, more than 90% of community pharmacies in England have provided it to their patients.
To inform the longer-term commissioning decision, the Department of Health (DH) commissioned researchers at the University of Nottingham to lead an academic evaluation of the service, investigating both the clinical and economic benefits of it. The findings from the evaluation were published in August 2014 and were overwhelmingly positive, with the researchers concluding that as the NMS delivered better patient outcomes for a reduced cost to the NHS, it should be continued. This was the basis for NHS England’s firm decision to continue commissioning the service.
PSNC and NHS Employers envisaged that the successful implementation of NMS would:
- improve patient adherence which will generally lead to better health outcomes;
- increase patient engagement with their condition and medicines, supporting patients in making decisions about their treatment and self-management;
- reduce medicines wastage;
- reduce hospital admissions due to adverse events from medicines;
- lead to increased Yellow Card reporting of adverse reactions to medicines by pharmacists and patients, thereby supporting improved pharmacovigilance;
- receive positive assessment from patients;
- improve the evidence base on the effectiveness of the service; and
- support the development of outcome and/or quality measures for community pharmacy.
Click on a heading below for more information.
Directions, guidance and service specification
The legal basis for the service is provided by the Secretary of State Directions. The service specification provides a ‘plain English’ version of the Directions and the official guidance from PSNC and NHS Employers provides essential information on the service for community pharmacy contractors, their staff and local NHS England teams (the successor bodies to PCTs).
These Directions have been amended a number of times since publication. The amendment Directions are printed in the Drug Tariff. PSNC has created a document which consolidates the 2013 Directions and subsequent amendments made up to December 2016.
PSNC and NHS Employers guidance on the NMS for contractors, their staff and local NHS England teams (updated in December 2013 to reflect the NHS re-organisation)
PSNC Briefing 033/15: Services Factsheet – NMS Medicines List (July 2015)
This Briefing outlines the requirements for patients to be eligible to receive the NMS service.
PSNC Briefing 016/14: Advanced Services (MURs and the NMS) (September 2014)
This PSNC Briefing summarises the changes being made to the Medicines Use Review (MUR) service in 2014/15 and it covers the re-commissioning of the New Medicine Service (NMS).
PSNC Briefing 087/13: Advanced services and Pre-registration Trainees (20th August 2013)
Following media reports that pre-registration trainees have been allowed to provide MUR and NMS consultations without supervision by a pharmacist, PSNC has issued guidance to pharmacy contractors.
Click on the links below for more information on that aspect of the service:
Notifying NHS England
| Knowledge & skills requirements
| Learning materials
| NMS medicines list
| Providing the NMS
| Obtaining patient consent
| Patient information
| Interview schedule
| NMS data requirements
| Communicating with GPs
| Referring patients to GPs
| Working with hospital colleagues
| Funding and claiming payment
| Service evaluation
| NMS statistics
| Other information
| Further NMS resources